Data are subject to national data protection laws and only available upon formal request. The KORA data are easily accessible via the online portal KORA.passt. (<https://epi.helmholtz-muenchen.de/>).

Introduction {#sec001}
============

Many factors, not only environment and lifestyle, but also genes, contribute to the development of type 2 diabetes (T2D) \[[@pone.0152314.ref001], [@pone.0152314.ref002]\]. The heritability of T2D and related traits has been estimated to be between 15 and 85% \[[@pone.0152314.ref003]--[@pone.0152314.ref007]\]. So far, 88 genetic susceptibility loci for T2D have been identified. However, these loci explain only 5--10% of the estimated heritability \[[@pone.0152314.ref008]--[@pone.0152314.ref013]\]. The analysis of DNA methylation patterns is expected to reveal epigenetic modifications associated with T2D at a genome-wide scale and may therefore hopefully help to clarify some of the missing heritability and improve our understanding of the pathomechanisms leading to T2D.

A small number of cross-sectional studies have provided first evidence for an association between DNA methylation and T2D. In skeletal muscle, peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator-1 alpha (PGC-1alpha) is hypermethylated in T2D patients compared to glucose tolerant individuals \[[@pone.0152314.ref014]\]. Furthermore, increased DNA methylation on the *FTO* obesity susceptibility haplotype was found when comparing human whole blood of 30 diabetic females and 30 females without diabetes \[[@pone.0152314.ref015]\]. A larger study comprising 710 T2D cases and 459 controls observed an excess of differentially methylated sites in genomic regions that are associated with T2D \[[@pone.0152314.ref016]\]. However, analyses of genome-wide DNA methylation and T2D-related traits as the phenotypes of interest in a population-based setting using whole blood have not been previously published.

Hallmarks in the pathogenesis of T2D are reduced insulin sensitivity and impaired insulin secretion, which eventually lead to chronic hyperglycemia \[[@pone.0152314.ref017], [@pone.0152314.ref018]\]. Therefore, we aimed to investigate (i) associations between DNA methylation and T2D-related traits \[glucose, insulin, HOMA-IR (homeostasis model assessment-insulin resistance)\]; (ii) the impact of BMI on these associations; (iii) associations between DNA methylation at the significant CpG sites and gene expression; and (iv) the enrichment for pathways linked to diabetes. To these ends, we performed epigenome-wide association studies (EWAS) using whole blood samples from a population-based prospective study, the Cooperative Health Research in the Region of Augsburg (KORA) F4 study. We provide evidence that the interaction of *ABCG1* with glucose metabolism is modulated by epigenetic processes.

Material/Methods {#sec002}
================

Ethics statement {#sec003}
----------------

The study was conducted according to the principles expressed in the Declaration of Helsinki. Written informed consent was obtained from all participants. The study, including the protocol for subject recruitment and assessment and the informed consent for participants, was reviewed and approved by the local ethical committee (Bayerische Landesärztekammer).

Study population {#sec004}
----------------

The KORA studies comprise a series of independent population-based epidemiological surveys and follow-up examinations of individuals living in the region of Augsburg and two adjacent counties in Southern Germany \[[@pone.0152314.ref019]\]. No evidence for population stratification in the KORA study was found \[[@pone.0152314.ref020]\].

DNA methylation data were generated for 1,814 participants of the KORA F4 study (2006--2008), who were randomly selected from a total of 3,080 KORA F4 participants aged between 32 and 81 years \[[@pone.0152314.ref021]\]. Fifteen samples were excluded upon quality control, resulting in 1,799 participants available for our study. In addition, 351 participants were excluded due to exhibiting at least one of the following criteria:

-   non-fasting (less than 8 hours),

-   overt diabetes (fasting glucose ≥ 7 mmol/l and/or 2-hour glucose ≥ 11.1 mmol/l and/or HbA1c ≥ 6.5% \[[@pone.0152314.ref022]\] and/or known diabetes and/or diabetes treatment),

-   unknown diabetes status as well as unclear information concerning the diabetes status,

-   missing values in at least one of the outcome parameters and/or covariates,

-   hsC-reactive protein \> 10 mg/l (as an indicator for an acute infection),

-   participants with fasting insulin ≥ 55.718 \[μlU/ml\] (corresponding to the 99^th^ percentile) as they clearly represented outliers in the dataset for this variable.

Data from 1,448 non-diabetic individuals aged between 32 and 81 years (see also [Table 1](#pone.0152314.t001){ref-type="table"}) were included in the EWAS of fasting glucose, 2-hour glucose, and HbA1c ([Fig 1](#pone.0152314.g001){ref-type="fig"}). For the EWAS of fasting insulin and HOMA-IR and 2-hour insulin, 1,440 (aged 32--81 years) and 617 (aged 62--81 years) participants were included, respectively ([S1](#pone.0152314.s001){ref-type="supplementary-material"} and [S2](#pone.0152314.s002){ref-type="supplementary-material"} Tables, [Fig 1](#pone.0152314.g001){ref-type="fig"}). Gene expression analyses were possible in a subgroup of 533 subjects aged 62 to 81 years for whom both gene expression data and methylation data were available ([S3 Table](#pone.0152314.s003){ref-type="supplementary-material"}, [Fig 1](#pone.0152314.g001){ref-type="fig"}) \[[@pone.0152314.ref023]\].

![Flow diagram for the study population.](pone.0152314.g001){#pone.0152314.g001}

10.1371/journal.pone.0152314.t001

###### Characteristics of the study population (n = 1,448) for the DNA methylation analyses of fasting glucose, 2-hour glucose, and HbA1c.
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                                                                              Median (25^th^; 75^th^ percentile)   \%
  --------------------------------------------------------------------------- ------------------------------------ ------
  **Sex \[% male\]**                                                          \-                                   47.1
  **Age \[years\]**                                                           59 (53; 67)                          \-
  **BMI \[kg/m**^**2**^**\]**                                                 27.1 (24.5; 30.1)                    \-
  **Waist circumference \[cm\]**                                              93.5 (84.5; 102.3)                   \-
  **Fasting serum glucose \[mmol/l\]**                                        5.3 (4.9; 5.6)                       \-
  **2-hour serum glucose \[mmol/l\]**                                         6.0 (5.0; 7.2)                       \-
  **HbA1c \[%\]**                                                             5.5 (5.2; 5.7)                       \-
  **Glucose tolerance status \[%\]**                                                                               
  NGT                                                                         \-                                   77.3
  IFG                                                                         \-                                   5.0
  IGT                                                                         \-                                   14.4
  Combined IFG and IGT                                                        \-                                   3.4
  **Fasting insulin \[μlU/ml\]**                                              4.1 (2.8; 6.7)                       \-
  **2-hour insulin \[μlU/ml\]**                                               50.2 (28.7; 412.0)                   \-
  **HOMA-IR**                                                                 1.0 (0.6; 1.6)                       \-
  **C-reactive protein \[mg/l\]**                                             1.2 (0.6; 2.2)                       \-
  **Leucocytes \[/nl\]**                                                      5.5 (4.7; 6.5)                       \-
  **Total cholesterol \[mmol/l\]**                                            5.7 (5.1; 6.4)                       \-
  **Triglycerides \[mmol/l\]**                                                1.2 (0.9; 1.7)                       \-
  **Systolic blood pressure \[mmHg\]**                                        122.2 (111.0; 134.5)                 \-
  **Diastolic blood pressure \[mmHg\]**                                       75.5 (69.5; 82.5)                    \-
  **Alcohol consumption \[g/day\]**                                           8.4 (0.0; 22.9)                      \-
  **Smoking status \[%\]**                                                                                         
  never                                                                       \-                                   44.8
  ex                                                                          \-                                   40.1
  current                                                                     \-                                   15.1
  **Physically active \[%\]**                                                 \-                                   
  (combination of activity during summer and winter with ≥ 1 hour per week)   \-                                   60.2

NGT: normal glucose tolerance. IFG: impaired fasting glucose. IGT: impaired glucose tolerance.

Assessment of diabetes-related traits {#sec005}
-------------------------------------

For the determination of fasting glucose and 2-hour glucose levels, fasting venous blood and blood samples after an oral glucose tolerance test (OGTT) for all non-diabetic participants were collected and analyzed as described elsewhere \[[@pone.0152314.ref024]--[@pone.0152314.ref026]\]. HbA1c values in blood were determined using high performance liquid chromatography (HPLC) (Menarini HA-8160) \[[@pone.0152314.ref024]\]. Fasting insulin was measured by ELISA \[[@pone.0152314.ref027]\]. HOMA-IR was calculated as \[fasting plasma glucose (mmol/l) x fasting serum insulin (mU/l) / 22.5\] \[[@pone.0152314.ref025]\]. Diabetes status was determined in all surveys via self-report. Self-reports were subsequently validated by contacting the treating physician or additionally performing an OGTT \[[@pone.0152314.ref024]\].

Genome-wide DNA methylation analysis {#sec006}
------------------------------------

Genomic DNA (1 µg), isolated from whole blood, was bisulfite converted using the EZ-96 DNA Methylation Kit (Zymo Research, Orange, CA, USA) as described recently \[[@pone.0152314.ref021]\]. Genome-wide DNA methylation was investigated using the Illumina HumanMethylation 450 BeadChip (Illumina, San Diego, CA, USA) following the Illumina Infinium HD Methylation instructions as described \[[@pone.0152314.ref021]\]. This array comprises \>485,000 CpG sites covering 99% of the genes in the reference sequence database \[[@pone.0152314.ref028]\]. Probes are distributed over the whole gene, including the promotor region, gene body, 3\`UTR, and intergenic region \[[@pone.0152314.ref028], [@pone.0152314.ref029]\]. Beta values representing continuous numbers between 0 and 1 reflecting the methylation degree were exported and used for statistical analysis, since methylation in this study is considered as the independent variable. GenomeStudio (version 2010.3) with Methylation Module (version 1.8.5) was used to process the raw image data generated by the BeadArray Reader. Initial quality control of assay performance was undertaken using "Control Dashboard" provided by GenomeStudio Software, including the assessment of staining, extension, hybridization, target removal, bisulfite conversion, specificity, negative, and non-polymorphic control.

Gene expression studies {#sec007}
-----------------------

Total RNA was extracted from whole blood taken under fasting conditions according to the manufacturer's instructions using the PAXgene Blood miRNA Kit (QIAGEN, Redwood City, CA, USA). Gene expression profiling was done using the Illumina Human HT-12 v3 Expression BeadChip (Illumina, San Diego, CA, USA) as described elsewhere \[[@pone.0152314.ref023], [@pone.0152314.ref030]\].

Statistical analysis {#sec008}
--------------------

The methylation data were preprocessed and quality controlled \[[@pone.0152314.ref021]\]. The CpG site-wise and sample-wise detection rates were set to 95%. The data were beta-mixture quantile normalized \[[@pone.0152314.ref031]\] with default parameter settings to avoid bias in the analysis due to the fact that two different chemistries are included on the chip \[[@pone.0152314.ref028]\]. Prior to modelling, the values of fasting glucose, 2-hour glucose, fasting insulin, and HOMA-IR were log transformed to achieve approximately normal distributions. Epigenome-wide associations between DNA methylation and measures of glucose metabolism (fasting glucose, 2-hour glucose, fasting insulin, HOMA-IR, and HbA1c) were assessed using linear mixed effects models (R package nlme), accounting for plate effects; see [Table 2](#pone.0152314.t002){ref-type="table"} for lists of covariates. Estimated white blood cell proportions were determined using the method published by Houseman *et al*. \[[@pone.0152314.ref032]\].

10.1371/journal.pone.0152314.t002

###### Regression models for the analysis of association between DNA methylation and measures of glucose metabolism.
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  Model    Covariates
  -------- ----------------------------------------------------------------
  **M1**   age, sex, estimated white blood cell proportions, smoking
  **M2**   age, sex, estimated white blood cell proportions, smoking, BMI

Furthermore, 2-hour insulin, cubic root transformed, was analyzed similarly for those CpG sites whose methylation levels showed genome-wide significance in model 1 for at least one of the phenotypes mentioned above, due to the smaller number of samples with available 2-hour insulin data. All results were corrected for multiple testing using the Benjamini-Hochberg (B-H) method \[[@pone.0152314.ref033]\]. We checked whether the detected CpG site contained SNPs with MAF ≥0.05 within the probe-binding regions. Cg09349128, cg15309457 and cg27434584 has to be regarded with caution as SNPs were included in the probe-binding region, which could lead to an influence of probe binding. Cross-reactive probes were checked using the list provided by Chen *et al*. \[[@pone.0152314.ref034]\]. For sensitivity analyses the study population was stratified according to DNA methylation quintiles for the CpG sites whose methylation levels showed significant associations with our phenotypes of interest, and p-values were determined using linear regression for continuous variables and Χ^2^ tests for categorical variables.

For a subset of 533 participants both methylation and gene expression data were available. In this subset the associations between methylation at the significant CpGs and gene expression at nearby genes were analyzed using linear regression models. Transcript probes that mapped to a ±500kb window around the CpG site were included. Models were adjusted for the gene expression specific technical variables \[[@pone.0152314.ref023]\] sample storage time, RNA integrity number (RIN), and RNA amplification batch, as well as for the methylation specific variables age, sex, BMI, smoking, estimated white blood cell proportions \[[@pone.0152314.ref032]\], and plate. We accounted for multiple testing using the B-H correction. For methylation as well as gene expression analysis results were defined as significant if the B-H-adjusted p-value was \<0.05. All statistical analyses were performed using R (version 2.15.3 or higher).

Pathway analysis {#sec009}
----------------

The Ingenuity Pathway Analysis (IPA) software (IPA build version: 364062M, content version: 26127183, release date: 2015-12-12, analysis date: 2016-01-08, <http://www.ingenuity.com/>) (QIAGEN, Redwood City, CA, USA) was used to detect potential pathways and networks in the DNA methylation data relevant in the cross-sectional study in an unbiased way. We included the 1,000 CpG sites with the smallest p-values for association with the respective traits and conducted pathway analysis separately for each trait. The database underlying IPA is referred to as the Ingenuity Knowledge Base (Gene and Endogenous Chemicals). The reference set was restricted to genes represented on the Illumina HT-12 v4 BeadChip, and only human annotations were considered. Pathway analyses were performed with IPA's Core Analysis module. Canonical pathways with a p-value \<0.05 after B-H correction were defined as a statistically significant overrepresentation of input genes in a given process.

Results {#sec010}
=======

Study population {#sec011}
----------------

Characteristics of the main study population of 1,448 individuals (for the analyses of fasting glucose, 2-hour glucose and HbA1c) are provided in [Table 1](#pone.0152314.t001){ref-type="table"}. [S1](#pone.0152314.s001){ref-type="supplementary-material"} and [S2](#pone.0152314.s002){ref-type="supplementary-material"} Tables give the corresponding information for the subgroups of 1,440 and 617 individuals for the analyses of fasting insulin/HOMA-IR and 2-hour insulin, respectively.

Association between DNA methylation and diabetes-related traits {#sec012}
---------------------------------------------------------------

In total, methylation levels of 31 CpG sites showed genome-wide significant associations with measures of glucose metabolism ([Table 3](#pone.0152314.t003){ref-type="table"}). Cg09349128, cg15309457 and cg27434584 have to be regarded with caution as SNPs were included in the probe-binding region with MAF \> 0.05, which could lead to an influence of probe binding. Methylation at five CpG sites showed genome-wide significant associations with fasting glucose in model 1 (B-H-adjusted p-values between 9.2x10^-5^ and 0.029) ([Fig 2A](#pone.0152314.g002){ref-type="fig"}). Results for cg22040809 (*HCG11*) have to be interpreted with caution as this site is listed by Chen *et al*. \[[@pone.0152314.ref034]\] as a cross-reactive probe, i.e. one that binds to another genomic sequence due to large sequence homology, the resulting signal therefore representing a mixture of methylation levels at different sites. One CpG site was associated with 2-hour glucose in model 1 (B-H-adjusted p-value 2.0x10^-3^) ([Fig 2B](#pone.0152314.g002){ref-type="fig"}). The methylation levels of eight CpG sites were associated with fasting insulin in model 1 (B-H-adjusted p-values between 3.0x10^-3^ and 0.017) ([Fig 2C](#pone.0152314.g002){ref-type="fig"}). HOMA-IR was associated with methylation status of 26 CpG sites in model 1 (B-H-adjusted p-values between 1.7x10^-4^ and 0.048) ([Fig 2D](#pone.0152314.g002){ref-type="fig"}). No genome-wide significant associations could be observed for HbA1c (data not shown). When we tested the association of all aforementioned CpG sites with 2-hour insulin, we observed significant associations for 21 CpG sites in model 1 (B-H-adjusted p-values between 9.0x10^-6^ and 0.042). In addition, we observed suggestive evidence for associations of CpG sites with fasting insulin (B-H-adjusted p-values 0.051) ([Table 3](#pone.0152314.t003){ref-type="table"}).

![Genome-wide associations between methylation and (a) fasting glucose, (b) 2-hour glucose, (c) fasting insulin, (d) HOMA-IR, after adjustment for sex, age, and estimated white blood cell proportions (model 1). Results are plotted for each chromosome (excluding the sex chromosomes) (x-axis) against the--log (unadjusted p-value) (y-axis). The Benjamini-Hochberg method was used as correction for multiple testing. The dotted line marks the significance threshold. Red dots: methylation levels of these CpG sites are associated with these phenotypes in model 1; turquois dots: methylation levels of these CpG sites are significantly associated with the phenotype after additional adjustment for BMI (model 2); blue dots: methylation levels of these CpG sites are significantly associated with the phenotype in both adjustment models.](pone.0152314.g002){#pone.0152314.g002}

10.1371/journal.pone.0152314.t003

###### Results for associations between genome-wide DNA methylation levels and fasting glucose, 2-hour glucose, fasting insulin, 2-hour insulin, and HOMA-IR, after adjustment for different potential confounders.
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                                                                Age, sex, estimated white blood cell proportions, smoking (model 1)   Age, sex, estimated white blood cell proportions, BMI, smoking (model 2)                                                                                                                                                                                           
  ------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------------- -------------- -------------------------------------------------------------------- --------- ------------ --------------------- -------------------- ------------ -------------------- --------------------
  **Fasting glucose**                                           cg00574958                                                            *CPT1A*                                                                    11:68607622    5\'UTR                                                               N Shore   **-0.097**   **9.8x10**^**-8**^    **0.014**            -0.060       5.8x10^-4^           0.985
                                                                cg06500161                                                            *ABCG1*                                                                    21:43656587    gene body                                                            S Shore   **0.044**    **4.2x10**^**-10**^   **9.2x10**^**-5**^   0.026        1.2x10^-4^           0.833
                                                                cg07504977                                                            unannotated                                                                10:102131012   \-                                                                   N Shelf   **0.023**    **2.0x10**^**-7**^    **0.022**            0.017        5.5x10^-5^           0.712
                                                                cg11024682                                                            *SREBF1*                                                                   17:17730094    gene body                                                            S Shelf   **0.056**    **2.5x10**^**-10**^   **9.2x10**^**-5**^   0.041        2.0x10^-6^           0.569
                                                                cg22040809[^\#^](#t003fn002){ref-type="table-fn"}                     *HCG11*                                                                    6:26522578     gene body                                                            Island    **-0.021**   **3.2x10**^**-7**^    **0.029**            -0.018       9.6x10^-6^           0.627
  **2-hour glucose**                                            cg06500161                                                            *ABCG1*                                                                    21:43656587    gene body                                                            S Shore   **0.042**    **4.6x10**^**-9**^    **2.0x10**^**-3**^   0.027        1.6x10^-4^           0.981
  **Fasting insulin**[\*](#t003fn003){ref-type="table-fn"}      cg03581271                                                            *PALLD*                                                                    4:169806766    gene body                                                            \-        0.032        2.5x10^-5^            0.183                **0.035**    **5.2x10**^**-7**^   **0.047**
                                                                cg06500161                                                            *ABCG1*                                                                    21:43656587    gene body                                                            S Shore   **0.043**    **6.9x10**^**-9**^    **3.0x10**^**-3**^   0.018        8.6x10^-3^           0.373
                                                                cg07092212                                                            *DGKZ*                                                                     11:46382544    gene body, TSS1500[^\$^](#t003fn006){ref-type="table-fn"}            \-        **-0.080**   **1.7x10**^**-7**^    **0.015**            -0.066       2.8x10^-6^           0.111
                                                                cg09613192                                                            unannotated                                                                2:181388538    \-                                                                   \-        **0.021**    **3.0x10**^**-7**^    **0.017**            0.013        4.7x10^-4^           0.331
                                                                cg09694782                                                            unannotated                                                                2:97408799     \-                                                                   S Shelf   **-0.037**   **5.8x10**^**-8**^    **0.011**            **-0.031**   **4.7x10**^**-7**^   **0.047**
                                                                cg11376147                                                            *SLC43A1*                                                                  11:57261198    gene body                                                            \-        **-0.076**   **2.1x10**^**-7**^    **0.015**            -0.041       2.3x10^-3^           0.340
                                                                cg13016916                                                            *CREB3L2*                                                                  7:137660322    gene body                                                            \-        0.016        1.2x10^-6^            0.051                **0.015**    **5.1x10**^**-7**^   **0.047**
                                                                cg17266233                                                            *DGKZ*                                                                     11:46382725    gene body, TSS1500[^\$^](#t003fn006){ref-type="table-fn"}            \-        **-0.102**   **1.6x10**^**-7**^    **0.015**            **-0.088**   **6.3x10**^**-7**^   **0.047**
                                                                cg17971578                                                            *STK40*                                                                    1:36852463     TSS1500                                                              S Shore   **-0.039**   **2.7x10**^**-7**^    **0.017**            -0.019       5.5x10^-3^           0.356
                                                                cg22065733                                                            unannotated                                                                8:11801320     \-                                                                   \-        **-0.067**   **7.2x10**^**-8**^    **0.011**            **-0.057**   **5.3x10**^**-7**^   **0.047**
                                                                cg23899654                                                            unannotated                                                                8:11759930     \-                                                                   Island    -0.073       1.4x10^-6^            0.051                **-0.068**   **6.1x10**^**-7**^   **0.047**
  **2-hour insulin**[\*\*\*](#t003fn005){ref-type="table-fn"}   cg00574958                                                            *CPT1A*                                                                    11:68607622    5\'UTR                                                               N_Shore   **-0.101**   **8.1x10**^**-4**^    **3.4x10**^**-3**^   -0.063       0.030                0.089
                                                                cg01751800                                                            *ANKRD56*                                                                  4:77820391     TSS1500                                                              S_Shore   **-0.017**   **0.016**             **0.031**            -0.014       0.032                0.089
                                                                cg02711608                                                            *SLC1A5*                                                                   19:47287964    1st Exon, 5\'UTR, gene body                                          N_Shelf   **-0.025**   **0.018**             **0.031**            -0.010       0.296                0.417
                                                                cg03979241                                                            *EPB49*                                                                    8:21916824     1st Exon, 5\'UTR[^\$^](#t003fn006){ref-type="table-fn"}              S_Shelf   **0.044**    **9.0x10**^**-4**^    **3.4x10**^**-3**^   **0.042**    **6.0x10**^**-4**^   **9.4x10**^**-3**^
                                                                cg04161365                                                            *DHRS13*                                                                   17:27230393    TSS1500                                                              S_Shore   **-0.030**   **0.016**             **0.031**            -0.018       0.120                0.196
                                                                cg06500161                                                            *ABCG1*                                                                    21:43656587    gene body                                                            S_Shore   **0.058**    **2.9x10**^**-7**^    **9.0x10**^**-6**^   **0.040**    **2.0x10**^**-4**^   **6.1x10**^**-3**^
                                                                cg06946797                                                            unannotated                                                                16:11422409    \-                                                                   \-        **-0.032**   **1.5x10**^**-4**^    **2.3x10**^**-3**^   **-0.025**   **1.4x10**^**-3**^   **0.012**
                                                                cg07504977                                                            unannotated                                                                10:102131012   \-                                                                   N_Shelf   **0.015**    **0.029**             **0.042**            0.010        0.106                0.196
                                                                cg09469355                                                            *SKI*                                                                      1:2161886      gene body                                                            S_Shore   **-0.036**   **9.8x10**^**-4**^    **3.4x10**^**-3**^   -0.020       0.059                0.141
                                                                cg09694782                                                            unannotated                                                                2:97408799     \-                                                                   S_Shelf   **-0.036**   **6.9x10**^**-4**^    **3.4x10**^**-3**^   **-0.031**   **1.6x10**^**-3**^   **0.012**
                                                                cg11024682                                                            *SREBF1*                                                                   17:17730094    gene body                                                            S_Shelf   **0.043**    **2.9x10**^**-3**^    **8.8x10**^**-3**^   0.031        0.022                0.076
                                                                cg11307565                                                            *PXN*                                                                      12:120701165   gene body                                                            N_Shore   **-0.046**   **4.6x10**^**-4**^    **3.4x10**^**-3**^   **-0.036**   **3.4x10**^**-3**^   **0.021**
                                                                cg11376147                                                            *SLC43A1*                                                                  11:57261198    gene body                                                            \-        **-0.077**   **7.4x10**^**-4**^    **3.4x10**^**-3**^   -0.046       0.036                0.094
                                                                cg11990813                                                            KIAA0664                                                                   17:2603739     gene body                                                            S_Shore   **0.067**    **3.5x10**^**-3**^    **9.1x10**^**-3**^   **0.058**    **7.7x10**^**-3**^   **0.034**
                                                                cg12593793                                                            unannotated                                                                1:156074135    \-                                                                   \-        **-0.037**   **6.7x10**^**-3**^    **0.016**            -0.010       0.439                0.545
                                                                cg13016916                                                            *CREB3L2*                                                                  7:137660322    gene body                                                            \-        **0.015**    **3.1x10**^**-3**^    **8.8x10**^**-3**^   **0.013**    **4.0x10**^**-3**^   **0.021**
                                                                cg15309457[\*](#t003fn003){ref-type="table-fn"}                       unannotated                                                                5:1746469      \-                                                                   Island    **-0.018**   **0.027**             **0.042**            -0.005       0.498                0.559
                                                                cg17588294                                                            unannotated                                                                2:129548156    \-                                                                   \-        **-0.031**   **0.012**             **0.026**            -0.020       0.086                0.177
                                                                cg17971578                                                            *STK40*                                                                    1:36852463     TSS1500                                                              S_Shore   **-0.044**   **5.0x10**^**-4**^    **3.4x10**^**-3**^   -0.022       0.067                0.147
                                                                cg20477259                                                            *TNF*                                                                      6:31544960     gene body                                                            N_Shelf   **-0.041**   **0.017**             **0.031**            -0.015       0.378                0.509
                                                                cg27434584[\*](#t003fn003){ref-type="table-fn"}                       *ESCO1*                                                                    18:19114052    gene body                                                            \-        **0.032**    **0.022**             **0.037**            0.032        0.015                0.057
  **HOMA-IR**[\*\*](#t003fn004){ref-type="table-fn"}            cg01751800                                                            *ANKRD56*                                                                  4:77820391     TSS1500                                                              S Shore   **-0.022**   **2.5x10**^**-6**^    **0.047**            -0.017       8.5x10^-5^           0.259
                                                                cg02711608                                                            *SLC1A5*                                                                   19:47287964    1st Exon, 5\'UTR, gene body[^\$^](#t003fn006){ref-type="table-fn"}   N Shelf   **-0.033**   **1.1x10**^**-6**^    **0.037**            -0.021       5.0x10^-4^           0.294
                                                                cg03979241                                                            *EPB49*                                                                    8:21916824     1st Exon, 5\'UTR[^\$^](#t003fn006){ref-type="table-fn"}              S Shelf   **0.037**    **2.8x10**^**-6**^    **0.048**            0.030        3.2x10^-5^           0.208
                                                                cg04161365                                                            *DHRS13*                                                                   17:27230393    TSS1500                                                              S Shore   **-0.040**   **1.3x10**^**-6**^    **0.038**            -0.028       1.4x10^-4^           0.273
                                                                cg06500161                                                            *ABCG1*                                                                    21:43656587    gene body                                                            S Shore   **0.047**    **3.9x10**^**-10**^   **1.7x10**^**-4**^   0.021        2.7x10^-3^           0.314
                                                                cg06946797                                                            unannotated                                                                16:11422409    \-                                                                   \-        **-0.027**   **6.6x10**^**-7**^    **0.029**            -0.017       3.3x10^-4^           0.287
                                                                cg07092212                                                            *DGKZ*                                                                     11:46382544    gene body, TSS1500[^\$^](#t003fn006){ref-type="table-fn"}            \-        **-0.083**   **5.6x10**^**-8**^    **5.6x10**^**-3**^   -0.067       9.5x10^-7^           0.057
                                                                cg09349128[\*](#t003fn003){ref-type="table-fn"}                       unannotated                                                                22:50327986    \-                                                                   N Shore   **-0.036**   **1.8x10**^**-6**^    **0.042**            -0.019       7.7x10^-3^           0.342
                                                                cg09469355                                                            *SKI*                                                                      1:2161886      gene body                                                            S Shore   **-0.034**   **1.6x10**^**-6**^    **0.040**            -0.019       3.1x10^-3^           0.316
                                                                cg09613192                                                            unannotated                                                                2:181388538    \-                                                                   \-        **0.021**    **3.4x10**^**-7**^    **0.019**            0.013        6.1x10^-4^           0.294
                                                                cg09694782                                                            unannotated                                                                2:97408799     \-                                                                   S Shelf   **-0.037**   **6.4x10**^**-8**^    **5.6x10**^**-3**^   -0.031       5.1x10^-7^           0.051
                                                                cg11307565                                                            *PXN*                                                                      12:120701165   gene body                                                            N Shore   **-0.040**   **2.8x10**^**-6**^    **0.048**            -0.029       2.4x10^-4^           0.287
                                                                cg11376147                                                            *SLC43A1*                                                                  11:57261198    gene body                                                            \-        **-0.079**   **5.1x10**^**-8**^    **5.6x10**^**-3**^   -0.043       1.2x10^-3^           0.306
                                                                cg11990813                                                            *KIAA0664*                                                                 17:2603739     gene body                                                            S Shore   **0.071**    **1.4x10**^**-6**^    **0.038**            0.059        6.7x10^-6^           0.149
                                                                cg12593793                                                            unannotated                                                                1:156074135    \-                                                                   \-        **-0.042**   **1.0x10**^**-6**^    **0.037**            -0.011       0.166                0.595
                                                                cg13016916                                                            *CREB3L2*                                                                  7:137660322    gene body                                                            \-        **0.016**    **8.7x10**^**-7**^    **0.035**            0.015        3.1x10^-7^           0.051
                                                                cg15309457[\*](#t003fn003){ref-type="table-fn"}                       unannotated                                                                5:1746469      \-                                                                   Island    **-0.025**   **1.9x10**^**-6**^    **0.042**            -0.017       5.5x10^-4^           0.294
                                                                cg17266233                                                            *DGKZ*                                                                     11:46382725    gene body, TSS1500[^\$^](#t003fn006){ref-type="table-fn"}            \-        **-0.102**   **1.4x10**^**-7**^    **0.010**            -0.087       5.7x10^-7^           0.051
                                                                cg17588294                                                            unannotated                                                                2:129548156    \-                                                                   \-        **-0.038**   **2.5x10**^**-6**^    **0.047**            -0.027       1.8x10^-4^           0.287
                                                                cg17971578                                                            *STK40*                                                                    1:36852463     TSS1500                                                              S Shore   **-0.039**   **1.8x10**^**-7**^    **0.011**            -0.019       5.7x10^-3^           0.334
                                                                cg18337963                                                            *DGKZ*                                                                     11:46383209    1st Exon, 5\'UTR, gene body[^\$^](#t003fn006){ref-type="table-fn"}   \-        **-0.069**   **1.5x10**^**-6**^    **0.038**            -0.063       1.3x10^-6^           0.057
                                                                cg20477259                                                            *TNF*                                                                      6:31544960     gene body                                                            N Shelf   **-0.055**   **6.5x10**^**-7**^    **0.029**            -0.031       2.6x10^-3^           0.313
                                                                cg22065733                                                            unannotated                                                                8:11801320     \-                                                                   \-        **-0.067**   **5.2x10**^**-8**^    **5.6x10**^**-3**^   -0.057       3.8x10^-7^           0.051
                                                                cg22798214                                                            unannotated                                                                1:212692190    \-                                                                   S Shelf   **-0.035**   **2.4x10**^**-6**^    **0.047**            -0.024       4.3x10^-4^           0.294
                                                                cg23899654                                                            unannotated                                                                8:11759930     \-                                                                   Island    **-0.072**   **1.4x10**^**-6**^    **0.038**            -0.068       5.6x10^-7^           0.051
                                                                cg27434584[\*](#t003fn003){ref-type="table-fn"}                       *ESCO1*                                                                    18:19114052    gene body                                                            \-        **0.041**    **2.6x10**^**-6**^    **0.047**            0.038        1.3x10^-6^           0.057

Results are presented with regression coefficients (increase in SD of phenotype per 1% increase in methylation), unadjusted p-values und B-H-adjusted p-values. Chromosome information is based on Genome Build 37.

^\#^ CpG site has to be regarded with caution as it is listed as a cross-reactive probe by Chen *et al*. \[[@pone.0152314.ref034]\].

\* CpG site has to be regarded with caution as SNPs were included in the probe-binding region, which could lead to an influence of probe binding.

\*\* Analyses for fasting insulin and HOMA-IR were performed with a reduced data set (n = 1,440).

\*\*\* Analyses for 2-hour insulin were performed with a reduced data set (n = 617) and only for CpG sites (n = 31) whose methylation levels were significantly associated with the other investigated phenotypes. TSS: Transcription start site.

^\$^ depending on transcription variant. CpG island: site with an accumulation of CpG sites. shore: located next to the CpG island. shelf: located more than 2kb away from the CpG island. S/N forward-space of shore or shelf: specifies the location in relation to the CpG island (N upstream the CpG island; S downstream the CpG site).

Impact of additional adjustment for BMI on associations between DNA methylation and diabetes-related traits {#sec013}
-----------------------------------------------------------------------------------------------------------

The methylation status of three CpG sites was still significantly associated with fasting insulin after additional adjustment for BMI in model 2 (B-H-adjusted p-values 0.047). Methylation of three additional CpG sites was found to be significant with this phenotype only in model 2 ([Table 3](#pone.0152314.t003){ref-type="table"}, [Fig 2C](#pone.0152314.g002){ref-type="fig"}). Methylation at seven CpG sites remained significantly associated with 2-hour insulin after adjustment for BMI in model 2 ([Table 3](#pone.0152314.t003){ref-type="table"}). In addition, we observed suggestive evidence for associations of some CpG sites with 2-hour insulin and HOMA-IR (B-H-adjusted p-values between 0.051 and 0.076) ([Table 3](#pone.0152314.t003){ref-type="table"}).

Comparing the coefficients in model 1 vs model 2 for each CpG site separately, the effect strengths were reduced on average by 29.2% (range 14.3--40.9%) for fasting glucose, suggesting a confounding or mediating effect of BMI. Furthermore, effect strengths were reduced by 36.1% for 2-hour glucose through adjustment for BMI, for fasting insulin on average by 23.6% (range 6.3--58.1%), for 2-hour insulin on average by 33.4% (range 3.2--72.5%), and for HOMA-IR on average by 29.8% (range 5.6--73.8%).

Distribution of metabolic variables in different DNA methylation quintiles {#sec014}
--------------------------------------------------------------------------

Next, we explored the relation between clinical phenotypes and methylation levels stratified into quintiles at eleven CpG sites significantly associated with fasting insulin and 2-hour insulin in model 2 \[cg03581271 (*PALLD*), cg17266233 (*DGKZ*), cg22065733 (unannotated), cg23899654 (unannotated), cg03979241 (*EPB49*), cg06500161 (*ABCG1*), cg06946797 (unannotated), cg09694782 (unannotated), cg11307565 (*PXN*), cg11990813 (*KIAA0064*), and cg13016916 (*CREB3L2*)\]. For cg06500161 (*ABCG1*) we observed significant associations between methylation and anthropometric as well as metabolic variables ([Table 4](#pone.0152314.t004){ref-type="table"}): the strongest associations were with waist circumference, triglycerides, fasting glucose, and BMI (p-values for trend \<10^−20^). In addition, strong associations between methylation and 2-hour glucose, CD8^+^ T cells, and monocytes (the last two being estimated quantities) (p-values for trend 10^−11^--10^−13^) were observed. For cg09694782 significant associations were observed with age, fasting insulin, and HOMA-IR, as well as for all estimated white blood cell proportions ([S4 Table](#pone.0152314.s004){ref-type="supplementary-material"}). For cg13016916 no significant associations could only be detected ([S5 Table](#pone.0152314.s005){ref-type="supplementary-material"}). For cg11990813 significant associations were found for fasting insulin, HOMA-IR, CD8^+^ T cells, CD4^+^ T cells, natural killer cells, and granulocytes ([S6 Table](#pone.0152314.s006){ref-type="supplementary-material"}). For cg11307565 significant associations were detected for BMI, fasting glucose, fasting insulin, HOMA-IR, CD8^+^ T cells, CD4^+^ T cells, natural killer cells, and granulocytes ([S7 Table](#pone.0152314.s007){ref-type="supplementary-material"}). For cg06946797 significant associations were observed for age, BMI, waist circumference, C-reactive protein, fasting insulin, 2-hour insulin, HOMA-IR, and almost all estimated white blood cell proportions ([S8 Table](#pone.0152314.s008){ref-type="supplementary-material"}). For cg03979241 a strong association could be detected for CD8^+^ T cells, CD4^+^ T cells, B cells, and granulocytes besides age, sex, and systolic blood pressure ([S9 Table](#pone.0152314.s009){ref-type="supplementary-material"}). For cg23899654 significant associations with 2-hour glucose, CD8^+^ T cells and granulocytes were observed ([S10 Table](#pone.0152314.s010){ref-type="supplementary-material"}). For cg22065733 significant associations with CD8^+^ T cells and granulocytes were found ([S11 Table](#pone.0152314.s011){ref-type="supplementary-material"}). For cg17266233 significant associations for the estimated white blood cell proportion of CD8^+^ T cells, B cells and granulocytes were detected ([S12 Table](#pone.0152314.s012){ref-type="supplementary-material"}) and for cg03581271 with fasting insulin ([S13 Table](#pone.0152314.s013){ref-type="supplementary-material"}).

10.1371/journal.pone.0152314.t004

###### Associations between DNA methylation at cg06500161 (*ABCG1*) and different phenotypes, based on quintiles of methylation level.
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                                                                                                            Quintile 1 (n = 290)   Quintile 2 (n = 289)                                             Quintile 3 (n = 290)                                               Quintile 4 (n = 289)                                              Quintile 5 (n = 290)                                               
  --------------------------------------------------------------------------------------------------------- ---------------------- ---------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------- ------------------------------------------------------------------ --------------
  Age \[years\] [\#](#t004fn002){ref-type="table-fn"}                                                       58.22 (8.77)           58.95 (8.44)                                                     60.50 (8.46)                                                       60.13 (8.53)                                                      61.47 (9.10)                                                       2.21x10^-5^
  BMI \[kg/m^2^\] [\#](#t004fn002){ref-type="table-fn"}                                                     26.01 (3.96)           27.09 (4.28)                                                     27.13 (3.99)                                                       28.10 (4.41)                                                      29.29 (4.45)                                                       8.30x10^-21^
  Waist circumference \[cm\]                                                                                87.39 (12.33)          92.04 (12.21)                                                    92.29 (11.27)                                                      95.93 (12.53)                                                     100.60 (12.42)                                                     1.20x10^-38^
  Fasting glucose \[mmol/l\] [\#](#t004fn002){ref-type="table-fn"}                                          5.12 (0.47)            5.24 (0.48)                                                      5.32 (0.53)                                                        5.36 (0.52)                                                       5.52 (0.55)                                                        4.80x10^-21^
  2-hour glucose \[mmol/l\] [\#](#t004fn002){ref-type="table-fn"}                                           5.71 (1.53)            6.16 (1.70)                                                      6.15 (1.72)                                                        6.28 (1.67)                                                       6.80 (1.75)                                                        5.82x10^-13^
  HbA1c \[%\]                                                                                               5.41 (0.33)            5.45 (0.32)                                                      5.45 (0.29)                                                        5.46 (0.32)                                                       5.57 (0.31)                                                        1.70x10^-7^
  C-reactive protein \[mg/l\] [\#](#t004fn002){ref-type="table-fn"}                                         1.68 (1.76)            1.61 (1.57)                                                      1.70 (1.57)                                                        1.80 (1.74)                                                       1.84 (1.67)                                                        1
  Fasting insulin \[μlU/ml\] [\#](#t004fn002){ref-type="table-fn"} [^1^](#t004fn004){ref-type="table-fn"}   5.03 (6.03)            6.17 (7.33)                                                      5.71(5.50)                                                         6.47 (6.24)                                                       7.92 (7.85)                                                        4.94x10^-6^
  2-hour insulin \[μlU/ml\] [\#](#t004fn002){ref-type="table-fn"} [^2^](#t004fn005){ref-type="table-fn"}    52.55 (43.42)          54.19 (41.80)                                                    57.59 (41.08)                                                      66.07 (50.52)                                                     81.47 (66.03)                                                      7.66x10^-6^
  HOMA-IR [\#](#t004fn002){ref-type="table-fn"} [^1^](#t004fn004){ref-type="table-fn"}                      1.17 (1.56)            1.47 (1.78)                                                      1.39 (1.44)                                                        1.58 (1.63)                                                       2.00 (2.16)                                                        1.93x10^-7^
  Cholesterol \[mmol/l\] [\#](#t004fn002){ref-type="table-fn"}                                              5.90 (0.97)            5.85 (0.97)                                                      5.79 (0.99)                                                        5.83 (1.02)                                                       5.63 (1.06)                                                        0.030
  Triglycerides \[mmol/l\] [\#](#t004fn002){ref-type="table-fn"}                                            1.09 (0.67)            1.25 (0.64)                                                      1.39 (1.22)                                                        1.59 (0.89)                                                       1.91 (1.23)                                                        7.79x10^-27^
  Systolic blood pressure \[mmHg\]                                                                          119.94 (19.09)         121.52 (16.38)                                                   125.01 (18.58)                                                     123.09 (17.78)                                                    126.97 (18.53)                                                     3.22x10^-5^
  Diastolic blood pressure \[mmHg\]                                                                         75.14 (10.25)          75.81 (8.89)                                                     76.77 (9.97)                                                       75.84 (9.78)                                                      77.5 (10.32)                                                       0.083
  CD8^+^ T cells +[\#](#t004fn002){ref-type="table-fn"}                                                     0.08 (0.05)            0.09 (0.06)                                                      0.10 (0.07)                                                        0.11 (0.07)                                                       0.12 (0.07)                                                        3.46x10^-13^
  CD4^+^ T cells +                                                                                          0.16 (0.06)            0.17 (0.06)                                                      0.16 (0.06)                                                        0.17 (0.06)                                                       0.16 (0.06)                                                        1
  Natural killer cells +[\#](#t004fn002){ref-type="table-fn"}                                               0.02 (0.02)            0.02 (0.02)                                                      0.03 (0.03)                                                        0.03 (0.03)                                                       0.03 (0.03)                                                        0.060
  B cells +[\#](#t004fn002){ref-type="table-fn"}                                                            0.05 (0.04)            0.05 (0.03)                                                      0.05 (0.02)                                                        0.05 (0.02)                                                       0.05 (0.02)                                                        1
  Monocytes +                                                                                               0.11 (0.02)            0.11 (0.02)                                                      0.12 (0.02)                                                        0.12 (0.02)                                                       0.12 (0.03)                                                        9.40x10^-11^
  Granulocytes +                                                                                            0.65 (0.09)            0.63 (0.09)                                                      0.63 (0.09)                                                        0.62 (0.09)                                                       0.62 (0.09)                                                        9.87x10^-6^
  **Categorical phenotypes**                                                                                **number**             **number (p-value)**                                             **number (p-value)**                                               **number (p-value)**                                              **number (p-value)**                                               **-**
  Sex \[male/female\]                                                                                       83/207                 122/167 (1.50x10^-3^[\*](#t004fn003){ref-type="table-fn"})       127/163 (1.00x10^-3^ [\*](#t004fn003){ref-type="table-fn"})        156/133 (5.00x10^-4^ [\*](#t004fn003){ref-type="table-fn"})       194/96 (5.00x10^-4^ [\*](#t004fn003){ref-type="table-fn"})         \-
  Glucose status \[combination of IFG and IGT/IFG/IGT/NGT\]                                                 3/8/21/258             8/6/46/229 (3.50x10^-3^ [\*](#t004fn003){ref-type="table-fn"})   11/13/40/226 (4.00x10^-3^ [\*](#t004fn003){ref-type="table-fn"})   6/23/46/214 (5.00x10^-4^ [\*](#t004fn003){ref-type="table-fn"})   21/22/55/192 (5.00x10^-4^ [\*](#t004fn003){ref-type="table-fn"})   \-

Means, standard deviations and p-values for trend are presented for the different quintiles for the continuous phenotypes. For the categorical variables total numbers of individuals in the different quintiles and p-values for the comparison of the corresponding quintile vs quintile 1 are given.

\# variables were log transformed for determination of p-values.

\* p-values are still significant after Bonferroni adjustment. + Proportions of cell types were estimated using method developed by Houseman *et al*. \[[@pone.0152314.ref032]\]

^1^ Variable only available for 1,440 samples, distribution between the quintiles (288/288/288/288/288).

^2^ Variable only available for 617 samples, distribution between the quintiles (124/123/123/123/124). IFG: impaired fasting glucose. IGT: impaired glucose tolerance. NGT: normal glucose tolerance.

Associations between methylation at the 18 identified significant CpG sites and transcript levels within a ± 500kb cis region {#sec015}
-----------------------------------------------------------------------------------------------------------------------------

The investigations of the associations between DNA methylation and gene expression at nearby genes (± 500kb cis area around significant CpG sites) were based on a subset of 533 participants with gene expression data available ([S3 Table](#pone.0152314.s003){ref-type="supplementary-material"}). Analyses were performed using linear regression and B-H correction for multiple testing. The methylation level at the CpG site cg06500161 (*ABCG1*) showed an inverse association with the *ABCG1* gene expression level (B-H-adjusted p-value = 1.5x10^-9^) after adjustment for age, sex, BMI, smoking, estimated white blood cell proportions, technical variables, and plate ([Table 5](#pone.0152314.t005){ref-type="table"}). This association was also detectable after additional adjustment for fasting glucose, 2-hour glucose, fasting insulin, 2-hour insulin or HOMA-IR (B-H-adjusted p-values = 1.2x10^-8^, 1.0x10^-8^, 2.3x10^-9^, 6.2x10^-8^, 3.3x10^-9^, respectively). The associations of gene expression levels with the other 30 significant CpG sites that were identified in the methylation analysis described above were not significant ([S14 Table](#pone.0152314.s014){ref-type="supplementary-material"}).

10.1371/journal.pone.0152314.t005

###### Summary of the analysis for association between DNA methylation and gene expression, and between DNA methylation and phenotypes.
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                                                                                                                               Coefficient   p-value       B-H-adj. p-value
  ---------------------------------------------------------------------------------------------------------------------------- ------------- ------------- ------------------
  **Association of methylation at cg06500161 (*ABCG1*) with different phenotypes**                                                                         
  **fasting glucose**                                                                                                          0.044         4.2x10^-10^   9.2x10^-5^
  **2-hour glucose**                                                                                                           0.042         4.6x10^-9^    2.0x10^-3^
  **fasting insulin**                                                                                                          0.043         6.9x10^-9^    3.0x10^-3^
  **2-hour insulin**                                                                                                           0.058         2.9x10^-7^    9.0x10^-6^
  **HOMA-IR**                                                                                                                  0.047         3.9x10^-10^   1.7x10^-4^
  **Association of methylation at cg06500161 and gene expression level of a transcript annotated to *ABCG1* (ILMN_2329927)**                               
  **no adj. for phenotype**                                                                                                    -3.647        1.9x10^-12^   1.5x10^-9^
  **adj. for fasting glucose**                                                                                                 -3.515        1.6x10^-11^   1.2x10^-8^
  **adj. for 2-hour glucose**                                                                                                  -3.535        1.3x10^-11^   1.0x10^-8^
  **adj. for fasting insulin**                                                                                                 -3.640        3.0x10^-12^   2.3x10^-9^
  **adj. for 2-hour insulin**                                                                                                  -3.419        8.0x10^-11^   6.2x10^-8^
  **adj. for HOMA-IR**                                                                                                         -3.617        4.3x10^-12^   3.3x10^-9^

The coefficient and unadjusted as well as B-H-adjusted p-value are presented.

Ingenuity Pathway Analysis {#sec016}
--------------------------

Pathway analyses based on the 1,000 CpG sites with the lowest p-values for association with fasting glucose showed an enrichment of fasting glucose-associated CpG sites (in model 1 and 2) in the pathway "Ephrin Receptor Signaling" at B-H-corrected levels of significance (p-values 0.041 and 0.035) ([Table 6](#pone.0152314.t006){ref-type="table"} and [Table 7](#pone.0152314.t007){ref-type="table"}). Furthermore, "Phospholipase C Signaling" showed suggestive evidence for enrichment in model 1 (B-H-adjusted p-value = 0.090) and in model 2 (B-H-adjusted p-values = 0.103) ([Table 6](#pone.0152314.t006){ref-type="table"} and [Table 7](#pone.0152314.t007){ref-type="table"}). Also "Axonal Guidance Signaling", "Adipogenesis Pathway", and "Molecular Mechanisms of Cancer" were detectable in both adjustment models (B-H-adjusted p-values 0.110 and 0.057) ([Table 6](#pone.0152314.t006){ref-type="table"} and [Table 7](#pone.0152314.t007){ref-type="table"}). Furthermore, "ERK/MAPK Signaling" pathway shows enrichment for fasting glucose-associated CpG sites in model 1 (B-H-adjusted p value = 0.110) ([Table 6](#pone.0152314.t006){ref-type="table"}). Finally, "Leptin Signaling in Obesity" shows enrichment for genes detected within the top 1,000 for adjustment model 2 as well "Ephrin A Signaling" (B-H-adjusted p-values = 0.057). Results for the top ten canonical pathways for 2-hour glucose, fasting insulin, and HOMA-IR are shown in [S15](#pone.0152314.s015){ref-type="supplementary-material"}, [S16](#pone.0152314.s016){ref-type="supplementary-material"}, [S17](#pone.0152314.s017){ref-type="supplementary-material"}, [S18](#pone.0152314.s018){ref-type="supplementary-material"}, [S19](#pone.0152314.s019){ref-type="supplementary-material"} and [S20](#pone.0152314.s020){ref-type="supplementary-material"} Tables.

10.1371/journal.pone.0152314.t006

###### Pathway analysis based on the top 1,000 CpG sites associated with fasting glucose (for results from model 1).
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  Ingenuity Canonical Pathways                B-H-adj. p-value   Ratio
  ------------------------------------------- ------------------ --------
  [Ephrin Receptor Signaling]{.ul}            0.041              17/172
  Phospholipase C Signaling                   0.090              19/231
  Axonal Guidance Signaling                   0.110              28/427
  Molecular Mechanisms of Cancer              0.110              24/359
  CCR3 Signaling in Eosinophils               0.110              11/113
  ERK/MAPK Signaling                          0.110              15/186
  Adipogenesis pathway                        0.110              12/132
  Aldosterone Signaling in Epithelial Cells   0.110              13/151
  Renal Cell Carcinoma Signaling              0.110              8/69
  Role of NFAT in Cardiac Hypertrophy         0.110              14/176

The p-value corrected using the Benjamini-Hochberg method for multiple testing and the ratio of the number of genes uploaded in the software/total number of genes included in the pathway are presented for each pathway. Underlined pathways are significant after correction for multiple testing using Benjamini-Hochberg.

10.1371/journal.pone.0152314.t007

###### Pathway analysis based on the top 1,000 CpG sites associated with fasting glucose (for results from model 2).
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  Ingenuity Canonical Pathways       B-H-adj. p-value   Ratio
  ---------------------------------- ------------------ --------
  [Ephrin Receptor Signaling]{.ul}   0.035              17/172
  Axonal Guidance Signaling          0.057              29/427
  Adipogenesis pathway               0.057              13/132
  Molecular Mechanisms of Cancer     0.057              25/359
  Leptin Signaling in Obesity        0.057              9/73
  RhoGDI Signaling                   0.057              15/172
  AMPK Signaling                     0.057              15/177
  Ephrin A Signaling                 0.057              7/48
  PPARα/RXRα Activation              0.072              14/165
  Phospholipase C Signaling          0.103              17/231

The p-value corrected using the Benjamini-Hochberg method for multiple testing and the ratio of the number of genes uploaded in the software/total number of genes included in the pathway are presented for each pathway. Underlined pathways are significant after correction for multiple testing using Benjamini-Hochberg.

Discussion {#sec017}
==========

To the best of our knowledge associations between methylation patterns in whole blood samples and parameters of glucose metabolism have not been previously reported in a large population-based study on a genome-wide scale. In the present study, we identified 31 CpG sites related to fasting glucose, 2-hour glucose, fasting insulin, 2-hour insulin, or HOMA-IR, independent of age, sex, smoking, and estimated white blood cell proportions. Three of these were also significantly associated with fasting insulin and seven with 2-hour insulin after additional adjustment for BMI (model 2). Additionally methylation of three CpG sites was significantly associated with fasting insulin in model 2. Furthermore, we found suggestive evidence for associations of methylation with 2-hour insulin and HOMA-IR after adjustment for BMI. By comparing the coefficients of each CpG site across the models, we determined the reduction of effect size through adjustment for BMI to be around 30% of the association. The general function of the detected genes is summarized in [S21 Table](#pone.0152314.s021){ref-type="supplementary-material"}. In an additional analysis, we found the strongest association between DNA methylation and different phenotypes and estimated white blood cell proportion for cg06500161. But also for all other CpG sites (excluded cg13016916), which were significantly associated with our markers of glucose metabolism after BMI adjustment, we detected associations with different phenotypes, mainly for estimated white blood cell proportions. As a second step we demonstrated an inverse association between DNA methylation and gene expression of the *ABCG1* gene. By performing an enrichment analysis of CpG sites for known biological pathways we detected several pathways which can be linked to diabetes. One aim of epigenetic studies is the elucidation of missing heritability for type 2 diabetes, related traits and many other outcomes. In this context, it is important to note that our findings cannot directly contribute to the clarification of missing heritability due to the cross-sectional study design. In order to address this aspect, prospective studies based on families will be required for which both genetic and epigenetic data are available so that their respective contributions to the heritable component of diabetes or glycaemic traits can be estimated.

Involvement of *ABCG1* in type 2 diabetes {#sec018}
-----------------------------------------

Using whole blood, we found association between the DNA methylation level of a CpG site annotated to *ABCG1* (ATP-binding cassette, sub-family G (WHITE), member 1) and all investigated phenotypes relating to glucose metabolism except HbA1c. Furthermore, DNA methylation of this CpG site was also inversely associated with its expression. Our findings support previous evidence by Hidalgo *et al*. who found an association between cg06500161 (*ABCG1*) and fasting insulin, as well as HOMA-IR, in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) study in CD4^+^ T cells. The authors did not adjust for BMI. In our study associations of cg06500161 with fasting glucose and 2-hour glucose (the latter not analyzed in their study) could be detected, and we further identified additional CpG sites associated with T2D-related traits that were not identified in the GOLDN study \[[@pone.0152314.ref035]\]. Possible explanations for the partly different findings include the different DNA sources (whole blood in our study versus CD4^+^ T cells in theirs), differences in data normalization, differences in multiple testing correction and different sample sizes. In our study, the associations with fasting glucose, 2-hour glucose, and HOMA-IR were attenuated when adjusting for BMI. As ABCG1 is an important regulator of cholesterol efflux from macrophages to HDL (high density lipoprotein) \[[@pone.0152314.ref036]\], this might have been expected considering that altered lipid levels, obesity and diabetes are associated, as shown in an analysis of serum samples from more than 5,000 men and women participating in the Framingham Heart Study \[[@pone.0152314.ref037]\]. Furthermore, low HDL-cholesterol is known as an independent risk factor for T2D \[[@pone.0152314.ref038]\]. Also in another study using our KORA samples an association between DNA methylation and lipid levels could be observed \[[@pone.0152314.ref039]\]. However, the connection between *ABCG1* and T2D/related traits as well as dyslipidemia is further supported by animal and human studies \[[@pone.0152314.ref040]--[@pone.0152314.ref045]\]. Taken together, our findings support a role of the *ABCG1* gene in the regulation of glucose metabolism and suggest that epigenetic mechanisms are involved in the association.

It is known that DNA methylation can influence the expression of genes \[[@pone.0152314.ref046]--[@pone.0152314.ref049]\]. From our findings that DNA methylation and gene expression of *ABCG1* are associated independently of our investigated phenotypes, we conclude that DNA methylation and gene expression may affect each other and therefore may have an influence on insulin or glucose levels. Our results cannot provide evidence for the direction of influence.

Relevance of the other associated CpG sites for type 2 diabetes {#sec019}
---------------------------------------------------------------

*SREBF1* (sterol regulatory element binding transcription factor 1), for which a significant association between methylation status and fasting glucose and 2-hour insulin was observed, has been linked to diabetes or related traits in human studies before \[[@pone.0152314.ref050], [@pone.0152314.ref051]\]. Also *TNF* (tumor necrosis factor) has been implicated in the development of type 2 diabetes. This latter gene encodes the proinflammatory cytokine TNFalpha that is secreted mainly by macrophages and overexpressed in adipose tissue \[[@pone.0152314.ref052]\]. It is involved in the regulation of lipid metabolism and insulin resistance \[[@pone.0152314.ref053], [@pone.0152314.ref054]\]. Animal studies demonstrate an association between TNFalpha and diabetes \[[@pone.0152314.ref055]--[@pone.0152314.ref057]\]. In cell culture experiments an association between TNFalpha and insulin resistance was observed \[[@pone.0152314.ref058], [@pone.0152314.ref059]\]. In human studies it was shown that the level of this cytokine is increased in T2D patients and subjects with insulin resistance \[[@pone.0152314.ref060], [@pone.0152314.ref061]\]. For *CPT1A* (carnitine palmitoyltransferase 1a), which is a key enzyme of fatty acid transport into mitochondria for beta-oxidation \[[@pone.0152314.ref062], [@pone.0152314.ref063]\], a link to diabetes or related traits can be found in animal and expression studies \[[@pone.0152314.ref063]--[@pone.0152314.ref065]\]. However, when analyzing SNPs at the *CPT1A* locus in diabetic and non-diabetic individuals, no association with T2D, hepatic lipid content or insulin resistance in T2D was observed \[[@pone.0152314.ref066]\]. Furthermore, a link between *PALLD* (palladin, cytoskeletal associated protein) and obesity has been reported \[[@pone.0152314.ref067]\]. For the amino acid transporter *SLC1A5* an enhanced expression was observed in goat mammary gland epithelial transfected cells \[[@pone.0152314.ref068]\]. Furthermore, the overexpression of GLUT1 and GLUT12 increases the expression of *SLC1A5* in goat mammary gland epithelial transfected cells \[[@pone.0152314.ref069]\]. Diaz *et al*. conclude from their experiments using transgenic mice overexpressing chicken Ski that *Ski* plays a main role in skeletal muscle metabolism and adipogenesis and therefore influence risk of obesity and diabetes \[[@pone.0152314.ref070]\]. This result was supported by findings of Leong *et al*. \[[@pone.0152314.ref071]\]. For *PXN* it was shown that glucose induces the activation of this paxillin, which is mediated by beta 1 integrin intracellular signaling \[[@pone.0152314.ref072]\].

Involvement of BMI in DNA methylation association {#sec020}
-------------------------------------------------

We showed that effect strengths were reduced on average by around 30% after adjustment for BMI, suggesting an influence of BMI on the investigated phenotypes.

In the literature evidence can be found that BMI is associated with DNA methylation patterns. For example Na *et al*. showed a differential influence of BMI on global DNA methylation when analyzing healthy women. They found a U-shaped association between BMI and Alu methylation, where the lowest methylation degree was found at a BMI between 23 and 30 kg/m^2^. These findings imply an involvement of BMI-related changes in Alu methylation in the etiology and pathogenesis of obesity \[[@pone.0152314.ref073]\]. Furthermore, allele-specific, age-dependent, and BMI-associated methylation at *MCHR1* was shown in human blood samples \[[@pone.0152314.ref074]\]. Furthermore, we could demonstrate in our study by trend analysis that the degree of methylation at cg06500161 rose with increasing measures of BMI. However, functional and/or time-series studies are needed to elucidate potential cause and effect mechanisms in the association between these genes, adiposity and glucose mechanisms.

As the previously discussed findings of our study indicate that BMI influences methylation, it is not unexpected that adjustment for BMI diminishes the association of selected CpG sites with the investigated measurements of glucose metabolism. Some CpG sites where associations seem to be mediated by BMI are biologically plausible in the context of T2D or related traits.

Association of gene expression and DNA methylation {#sec021}
--------------------------------------------------

We demonstrate an inverse association between DNA methylation and gene expression of the *ABCG1* gene. In general this finding is not surprising due to the fact that hypermethylation within the gene promotor and shores is mostly associated with a reduced gene expression \[[@pone.0152314.ref075]--[@pone.0152314.ref078]\]. Recent studies demonstrate that methylation in the gene body may lead to increased rather than decreased gene expression \[[@pone.0152314.ref079], [@pone.0152314.ref080]\], which would be in contrast to our findings. However, due to lack of general evidence further studies will be required to elucidate the mechanisms underlying our findings, as this cannot be achieved in an epidemiological setting. The particularly strong association between methylation at cg06500161 and the markers of glucose metabolism seems reflected by the fact that we can only demonstrate an association of methylation and gene expression for this gene after correction for multiple testing, whereas associations for other CpG sites were significant only before correction for multiple testing. It should be noted that the sample size for the gene expression analyses was limited to 533 samples and therefore statistical power may have been lower compared to the analysis between methylation and phenotypes. Additional 23 CpG sites show an association with gene expression in the unadjusted analysis ([S14 Table](#pone.0152314.s014){ref-type="supplementary-material"}).

Enrichment of signals from biological pathways and link to diabetes {#sec022}
-------------------------------------------------------------------

In order to functionally integrate our results, we conducted a pathway analysis based on the 1,000 top hits for each phenotype and each model. Some of the identified pathways have a well-established link to diabetes or related traits. One example is the "Adipogenesis Pathway". An *et al*. show that cyclin Y is involved in adipogenesis and lipid accumulation and that its inhibition could be a therapeutic approach to obesity and diabetes \[[@pone.0152314.ref081]\]. Furthermore, it was shown that adipose cell expansion is associated with abdominal obesity and insulin resistance \[[@pone.0152314.ref082]\] and that there is an association between genetic predisposition for T2D and adipocyte hypertrophy \[[@pone.0152314.ref083]\]. Another example is "Phospholipase C Signaling". A contribution of phospholipase C delta1 to obesity through regulation of thermogenesis and adipogenesis in mice was observed \[[@pone.0152314.ref084]\], as were its effects on insulin secretion in a pancreatic beta-cell line \[[@pone.0152314.ref085]\]. A link to diabetes can also be found for "Leptin Signaling in Obesity", as leptin is involved in the regulation of obesity, which in turn is an important risk factor for T2D \[[@pone.0152314.ref086]\]. A further link to diabetes exists for "Ephrin Receptor Signaling" and "Ephrin A/B Signaling". It was shown that EphA and ephrin A regulate insulin secretion \[[@pone.0152314.ref087]\] and that the communication between ephrin receptors and ephrin in exocrine and endocrine cells is involved in pancreatic function \[[@pone.0152314.ref088]\]. Ephrin receptors and ephrins are expressed in pancreatic beta-cells in humans and mice \[[@pone.0152314.ref089]\] and EphAs are tyrosine phosphorylated under low glucose concentrations and initiate forward signaling, which in turn reduces insulin secretion \[[@pone.0152314.ref090]\]. Finally, there is evidence for linking "ERK/MAPK Signaling" to diabetes, as it was shown that MAPK/ERK signaling controls glucose metabolism by regulating insulin sensitivity in Drosophila \[[@pone.0152314.ref091]\]. Furthermore, an association between sustained activation of ERK signaling in adipocytes and the pathogenesis of T2D was found \[[@pone.0152314.ref092]\]. Additional, Hsp60 activates ERK1/2 in skeletal muscle cells and thus inhibits insulin signaling and insulin-stimulated glucose uptake \[[@pone.0152314.ref093]\]. Taken together, we observe an enrichment of our detected genes in pathways which are connected to diabetes or related traits. From this we conclude that our results, although not always significant, are biologically plausible in the context of measures of glucose metabolism and may be the basis for further analysis.

Strengths/Limitations {#sec023}
---------------------

The main strength of this study is the use of whole blood samples, as whole blood is readily available in the clinical routine, unlike tissue biopsies, and therefore has greater relevance in the context of the prediction of diabetes. On the other hand, this is also a limitation, as it is known that DNA methylation patterns differ across tissues \[[@pone.0152314.ref032]\] and whole blood thus represents a mixture of cell types and may differ in methylation profile from insulin-responsive tissues like liver, skeletal muscle and adipose tissue. However, we adjusted for estimated white blood cell proportions derived from methylation data for blood cells in order to reduce confounding due to inter-individual differences in blood cell proportions.

Further strengths of our study are the genome-wide approach and the population-based design. Our study also included oral glucose tolerance tests so that data for 2-hour glucose and 2-hour insulin were available. However, a major caveat of our cross-sectional study design is that it does not allow deductions on cause and effect. Finally, meta-analyses of EWAS of glycemic traits will have a larger power to detect further CpG sites whose methylation levels did not reach statistical significance in our study.

Conclusion {#sec024}
==========

Our study presents evidence of association between DNA methylation and measures of glucose metabolism, using whole blood samples from individuals with European ancestry. Our findings show that epigenetic markers associated with measures of glucose metabolism can be detected in whole blood samples, and they confirm previous evidence that *ABCG1* is involved in diabetes either directly or indirectly. Furthermore, we confirm recent findings found in CD4^+^ T cells--as well as from participants with Indian Asian ancestry--from the GOLDN and LOLIPOP studies, which demonstrated an association between methylation degree of cg06500161 (*ABCG1*) and measures of glucose metabolism and incident T2D \[[@pone.0152314.ref035], [@pone.0152314.ref045]\]. In addition we detected enrichment of differentially methylated genes in pathways which are biologically plausible in the context of diabetes. The findings provide evidence that DNA methylation may be associated with T2D and related traits, a relationship which can be measured in DNA isolated from whole blood. Particularly, epigenetic patterns of disease-relevant tissues might further advance our understanding of how DNA methylation at the identified genes is involved in diabetes and therefore its pathophysiology. However, for ethical and practical reasons, DNA methylation analyses are often only feasible in whole blood rather than in disease-relevant tissues, particularly in large population-based observational studies.
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